SILVER SPRING, Md., Feb. 10, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at

PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on the report saying, “In our opinion the Research Report released by Stonegate Capital Partners and authored by Senior Research Analyst Laura S. Engel is comprehensive and captures the essence of what we are trying to accomplish at PharmaCyte. Particular emphasis is placed on the two major programs underway that employ our proprietary Cell-in-a-Box® live-cell encapsulation technology to tackle two of the most difficult to treat diseases in the world - cancer and diabetes.”

Stonegate’s Senior Research Analyst, Laura S. Engel, authored the Research Report, which focuses on PharmaCyte’s clinical development of a variety of potential therapies across several areas of disease utilizing its novel live cell encapsulation platform, Cell-in-a-Box®.  

Stonegate’s Senior Research Analyst writes that PharmaCyte offers a significant opportunity for investors looking to participate in this development. “We believe that PMCB has a solid pathway towards commercialization with the approach outlined for its Phase 2b study for pancreatic cancer patients set to begin in the Q2-Q3 of calendar year 2016. Additionally, management will be actively moving other potential treatments along; these treatments are related to malignant ascites fluid accumulation in the abdomens of patients with abdominal cancers and Type 1 and Type 2 diabetes. Positive news flow should yield investor returns as the Company accomplishes its milestones that have been set for 2016.”

Senior Research Analyst Laura S. Engel started a career in public accounting following graduation from the University of Virginia, McIntire School of Business, with a B.S. in Accounting. After several years with Arthur Andersen, Engel transitioned in industry where she worked for several publicly traded companies, managing both domestic and international accounting operations. Engel subsequently transitioned into the finance realm, joining a Financial Services consulting team with KPMG Consulting focusing on systems implementations for several Wall Street banks. She later joined a smaller wealth management group, servicing a book of clientele through investment management and financial planning. Since 2003, Engel has teamed with Stonegate and worked in several areas of the business.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (prodrug) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor

This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.  

More information about PharmaCyte Biotech can be found at It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856

Primary Logo

Source: PharmaCyte Biotech, Inc.